News

Censo Biotechnologies joins The Milner Institute as an Affiliated Partner

April 24th 2017

The Milner Therapeutics Institute is a global therapeutic alliance based in Cambridge, dedicated to the conversion of basic science into therapies. Censo Biotechnologies is delighted to join The Institute as an Affiliated Partner and looks forward to developing new partnerships in both academic and industry.

Read
News

A humanized phenotypic screening platform for chronic pain - Join Our Webinar

February 27th 2017

Physiologically relevant human models of chronic pain are essential to developing new therapeutics and overcome poor translation between animal studies and the clinical setting. Join us, as co-host, in a free webinar on stem cell-based pain and CNS drug discovery to learn more.

Read
News

Cellectricon and Censo Biotechnologies introduce a joint technology access program utilizing high-quality Human iPSC-based discovery services for CNS and pain research

January 27th 2017

Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.

Read
News

Cellectricon and Censo Biotechnologies collaborate to offer high-quality Human iPSC-based discovery services for CNS and pain research

September 8th 2016

Mölndal, Sweden and Cambridge, UK – 8th September 2016 – Cellectricon AB, a leading provider of advanced cell-based discovery screening services, today announced a commercial collaboration with UK-based stem cell technology company Censo Biotechnologies Ltd. Under the agreement, the parties will provide a suite of high-quality Human iPSC based discovery services to support both preclinical neuroscience and chronic pain research.

Read

Bipolar disorder stem cells to be deposited with EBiSC

August 10th 2016

A unique set of stem cells derived from patients with bipolar disorder are to be deposited with the European Bank for Induced Stem Cells (EBiSC). The cell lines were made by researchers from the University of Edinburgh in a project funded by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) through the CRACK IT Challenge programme. The cell lines are being banked and tested by Roslin Cell Sciences, part of the Censo Biotechnologies Group, which also operates the EBiSC central facility. By depositing these cells with EBiSC they will become available to expert researchers worldwide and enable a better understanding of the disorder and will help develop new treatments.

Read

Roslin stem cell companies combine to create Censo Biotechnologies group.

May 10th 2016

The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focussed on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary.

Read

Launch of new European Stem Cell Bank

March 23rd 2016

EBiSC, the European Bank for induced pluripotent Stem Cells announces the public launch of its on-line catalogue of induced Pluripotent Stem Cells (iPSCs) which are available to academic and commercial scientists for use in disease modelling and other forms of pre-clinical research.

Read

Roslin Cell Sciences relocates to larger premises at Roslin BioCentre

February 28th 2016

Roslin Cell Sciences, a wholly owned subsidiary of Roslin Cells Ltd, has moved its operations for production of human pluripotent stem cells (iPSCs) for drug discovery to the Roslin BioCentre.

Read